Partial
Partially Aligned
Patient Risk:
Low
Summary
The supplied Ibrance prescribing information contains no patent, exclusivity, or generic-entry information. The specific patent and launch-timing claims therefore cannot be verified from the label; the caveat that they are not label-supported is appropriate.
Category Scores
Accurate Statements
The claims concern patent terms, exclusivity, and anticipated generic entry, which are not addressed in the supplied prescribing information and cannot be verified from it.
No FDA label sections were supplied; the listed patent and generic-entry subjects are absent from the available label material.
Being absent from the label does not establish that the claims are factually correct.
The supplied label material provides no information with which to verify these claims.
Unsupported Statements
The core patents covering palbociclib were filed in the early 2000s, and most expire in 2024–2026.
Patent filing and expiration dates are not addressed in the supplied prescribing information.
Pfizer holds secondary patents on Ibrance formulations, delivery systems, and specific uses that run through the early 2030s.
The supplied prescribing information does not describe patent holdings or patent expiration dates.
Ibrance is protected in the United States until around 2027–2032, and generics are expected, if at all, to launch in the 2027–2032 window.
The supplied prescribing information does not address market protection or expected generic launch timing.
A standard product patent lasts 20 years from filing, and product patents filed in 2003–2005 are expected to expire in 2024–2026.
General patent-term rules and the dates of Ibrance patents are not stated in the supplied prescribing information.
Method-of-use and formulation patents last 20 years from filing, and patents filed in 2007–2010 are expected to expire in 2027–2032.
Patent terms and filing dates are not stated in the supplied prescribing information.
An FDA patent term extension for a drug approved in 2015 lasts 17 years from approval and expires in 2032.
The supplied prescribing information does not discuss patent term extensions or this asserted timeline.
The FDA gives new drugs an additional 17-year patent term beyond the 20-year filing rule.
This patent-law assertion is not addressed in the supplied prescribing information.
For Ibrance, a patent term extension pushes final expiry to 2032.
The supplied prescribing information does not identify an Ibrance patent term extension or a final patent expiry.
As of 2026, no FDA-approved generic version of Ibrance has entered the market.
The supplied prescribing information does not provide generic approval or market-entry status.
Generic manufacturers typically wait until relevant patents expire or are successfully challenged before filing an Abbreviated New Drug Application.
Generic manufacturers' filing practices are not addressed in the supplied prescribing information.
When the last method-of-use or formulation patents expire, likely in 2027–2028, there could be a 3–4-year period before the stated 2032 patent term runs out.
The asserted patent dates and resulting timeline are not supported by the supplied prescribing information.
Multiple generic competitors might file Abbreviated New Drug Applications during that period.
Potential generic filings are not addressed in the supplied prescribing information.
Pfizer may file new patents on dosing schedules, combination therapies, or delivery devices that could postpone generic entry further.
The supplied prescribing information does not address future patent filings or their effect on generic entry.
Generic entry for Ibrance is most likely in 2027–2029 if no additional patents are granted.
The supplied prescribing information does not project generic-entry timing.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims concern patents and generic-entry timing, not dosing, administration, or patient safety. No label-based safety conflict can be assessed from the supplied material.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Specific patent and generic-entry assertions are not verifiable from the supplied prescribing information.
Suggested Improvement
Clearly distinguish claims that are outside the scope of the prescribing information from facts verified by the label; do not present patent timelines as label-supported.